HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin

International Journal of Oncology

Volumn 32, Issue 4, 2008, Pages 821-827

  Svechnikova, Irina ^a   Almqvist, Per M ^a   Ekström, Tomas J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Differentiation; Glioblastoma; Phenylbutyrate; Trichostatin A

Indexed keywords

4 PHENYLBUTYRIC ACID; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTONE DEACETYLASE INHIBITOR; NESTIN; TRICHOSTATIN A; VIMENTIN; ARYLBUTYRIC ACID DERIVATIVE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL SPECIFICITY; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; GLIOBLASTOMA; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; PHENYLBUTYRATES;

EID: 44449135127     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Huang Y and Waxman S: Enhanced growth inhibition an differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin Cancer Res 4: 2503-2509, 1998
2. Bar-Ner M, Thibault A, Tsokos M, Magrath IT and Samid D: Phenylbutyrate induces cell differentiation and modulate Epstein-Barr virus gene expression in Burkitt's lymphoma. cell Clin Cancer Res 5: 1509-1516, 1999.
3. Gore SD, Samid D and Weng LJ: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 3: 1755-1762, 1997.
4. Calvaruso G, Carabillo M, Giuliano M, et al: Sodium phenylbutyrate induces apoptosis in human retinobWtoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan. Int J Oncol 18: 1233-1237, 2001.
5. Melchior SW, Brown LG, Figg WD, et al: Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol 14: 501-508, 1999.
6. Engelhard HH, Homer RJ, Duncan HA and Rozental J: Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J Neurooncol 37: 97-108, 1998.
7. Li XN, Parikh S, Shu Q, et al: Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 10: 1150-1159, 2004.
8. Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P and Ekström TJ: Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 22: 579-588, 2003.
9. Gilbert J, Baker SD, Bowling MK, et al: A phase I dos escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7: 2292-2300, 2001.
10. Carducci MA, Gilbert J, Bowling MK, et al: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on a 120-h infusion schedule. Clin Cancer Res 7: 3047-3055, 2001.
11. Gore SD and Carducci MA: Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs 9: 2923-2934, 2000.
12. Bowling MK, Nelson JB, Tong KP, et al: Biomarker response in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB). Proc Am Soc Clin Oncol 15: A43, 1996.
13. Gore SD, Miller CB, Weng LJ, et al: Clinical development of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies. Anticancer Res 17: 3938, 1997.
14. Fisher JD, Carducci MA, Baker SD, et al: Dose escalation stud of oral sodium phenylbutyrate (PB) in patients with refractory high grade astrocytomas: maximum tolerated dose, toxicity profile, pharmacology and survival. Proc Am Soc Clin Oncol 49: 166a, 2000.
15. Witzig TE, Timm M, Stenson M, Svingen PA and Kaufmann SH: Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 6: 681-692, 2000.
16. Sung MW and Waxman S: Chemodifferentiation therapy with fluorouracil and phenylbutyrate in advanced colorectal cancer: a Phase I trial. Proc Am Assoc Cancer Res 40: 339, 1999.
17. Pili R, Kruszewski MP, Hager BW, Lantz J and Carducci MA: Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61: 1477-1485, 2001.
18. Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999.
19. Samid D, Ram Z, Hudgins WR, et al: Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 54: 891-895, 1994.
20. Pineau T, Hudgins WR, Liu L, et al: Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52: 659-667, 1996.
21. Yoshida M, Kijima M, Akita M and Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179, 1990.
22. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
23. Gray SG and Ekstrom TJ: The human histone deacetylase family. Exp Cell Res 262: 75-83, 2001.
24. Vigushin DM, Ali S, Pace PE, et al: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001.
25. Chen Z, Clark S, Birkeland M, et al: Induction and super-induction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett 188: 127-140, 2002.
26. Wang ZM, Hu J, Zhou D, Xu ZY, Panasci LC and Chen ZP: Trichostatin A inhibits proliferation and induces expression of p21WAF and p27 in human brain tumor cell lines. Aizheng 21: 1100-1105, 2002.
27. Kelly WK, Richon VM, O'Connor O, et al: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588, 2003.
28. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N and Horinouchi S: Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48: S20-S26, 2001.
29. Gui CY, Ngo L, Xu WS, Richon VM and Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246, 2004.
30. Archer SY, Meng S, Shei A and Hodin RA: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
31. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S and Beppu T: Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 214: 189-197, 1994.
32. Munro J, Barr NI, Ireland H, Morrison V and Parkinson EK: Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp Cell Res 295: 525-538, 2004.
33. Gray SG, Eriksson T and Ekstrom TJ: Methylation, gene expression and the chromatin connection in cancer (review). Int J Mol Med 4: 333-350, 1999.
34. Sambucetti LC, Fischer DD, Zabludoff S, et al: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947, 1999.
35. Takakura M, Kyo S, Sowa Y, et al: Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29: 3006-3011, 2001.
36. Asklund T, Appelskog IB, Ammerpohl O, et al: Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res 284: 185-195, 2003.
37. Enblad P, Hesselager G, Bongcam-Rudloff E, Hallin I, Westermark B and Nister M: Modulation of phenotype and induction of irregular vessels accompany high tumorigenic potential of ctonal human glioma cells xenografted to nude-rat brain. Int J Cancer 85: 819-828, 2000.
38. Lendahl U, Zimmerman LB and McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell 60: 585-595, 1990.
39. Tsubaki J, Choi WK, Ingermann AR, et al: Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells. J Endocrinol 169: 97-110, 2001.
40. Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T and Hashimoto-Tamaoki T: Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer 76: 897-902, 1998.
41. Carducci MA, Nelson JB, Chan-Tack KM, et al: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2: 379-387, 1996.
42. Engelhard HH, Duncan HA and Dal Canto M: Molecular characterization of glioblastoma cell differentiation. Neurasurgery 41: 886-897, 1997.
43. Paramio JM and Jorcano JL: Beyond structure: do intermediate filaments modulate cell signalling? Bioessays 24: 836-844, 2002.
44. Hendrix MJ, Seftor EA, Chu YW, Trevor KT and Seftor RE: Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 15: 507-525, 1996.
45. Nister M and Westermark B: Human glioma cells. In: Atlas of Human Tumor Cell Lines. Hay RJ, Park JG and Gazdar A (eds). Academic Press Inc., New York, pp 17-42, 1994.
46. Almqvist PM, Mah R, Lendahl U, Jacobsson B and Hendson G: Immunohistochemical detection of nestin in pediatric brain tumors. J Histochem Cytochem 50: 147-158, 2002.
47. Libermann TA, Nusbaum HR, Razon N, et al: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147, 1985.
48. Westermark B, Magnusson A and Heldin CH: Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res 8: 491-507, 1982.